Loading…
The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole
The majority of inhibitory neurotransmission in the brain is mediated by the gamma-aminobutyric acid (GABA) type A (GABA(A)) receptor. The anticonvulsant loreclezole largely acts by potentiating GABA(A) receptors containing beta2 and beta3 subunits. We used a genetically modified mouse containing a...
Saved in:
Published in: | The European journal of neuroscience 2006-07, Vol.24 (1), p.167-174 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 174 |
container_issue | 1 |
container_start_page | 167 |
container_title | The European journal of neuroscience |
container_volume | 24 |
creator | Groves, James O Guscott, Martin R Hallett, David J Rosahl, Thomas W Pike, Andrew Davies, Amy Wafford, Keith A Reynolds, David S |
description | The majority of inhibitory neurotransmission in the brain is mediated by the gamma-aminobutyric acid (GABA) type A (GABA(A)) receptor. The anticonvulsant loreclezole largely acts by potentiating GABA(A) receptors containing beta2 and beta3 subunits. We used a genetically modified mouse containing a loreclezole-insensitive beta2 subunit (beta2N265S) to determine the role of this subunit in mediating the sedative and anticonvulsive effects of loreclezole. Sedation was assessed by measuring spontaneous locomotor activity and beam walking performance, and anticonvulsant efficacy was determined by pentylenetetrazole (PTZ) and amygdala kindling-induced seizures. The beta2N265S mice did not exhibit loreclezole-mediated sedation as shown by normal locomotor activity and beam walking performance. However, loreclezole also failed to provide significant protection against PTZ-induced seizures in the beta2N265S mice. Reduced efficacy against amygdala-kindled seizures, both acutely and over a 13-day chronic dosing study, was also observed in beta2N265S mice. These results suggest that the majority of the sedative effects and a significant proportion of the anticonvulsant efficacy of loreclezole are mediated via beta2-containing GABA(A) receptors. |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68707330</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68707330</sourcerecordid><originalsourceid>FETCH-LOGICAL-p544-6abcd8180cb4810f919aba16315fc897057cfd5335834324546ba668c1c3818d3</originalsourceid><addsrcrecordid>eNo1kD1PwzAQhjOAaCn8BeSJLZIdf8QZSwUFqRJLB7bIds5g5NohdirBr8cVZbqv931OdxfVEnec1pKIt0V1ndInxlgKxq-qBRFSNpiwZXXcfwCaogcULdquH9YasmpQmvUcXK5NDFm54MI7msDAmOOUkAvoAINT-dTOxa9CdkV5nH0qaSkHlGAo8yMgsBZMTie8j4Xh4adsu6kurfIJbs9xVe2fHveb53r3un3ZrHf1yBmrhdJmkERio5kk2HakU1oRQQm3RnYt5q2xA6eUS8powzgTWgkhDTG02Aa6qu7_sOMUv2ZIuT-4ZMB7FSDOqReyxS2luAjvzsJZl9v6cXIHNX33_4-iv5ktZL4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68707330</pqid></control><display><type>article</type><title>The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Groves, James O ; Guscott, Martin R ; Hallett, David J ; Rosahl, Thomas W ; Pike, Andrew ; Davies, Amy ; Wafford, Keith A ; Reynolds, David S</creator><creatorcontrib>Groves, James O ; Guscott, Martin R ; Hallett, David J ; Rosahl, Thomas W ; Pike, Andrew ; Davies, Amy ; Wafford, Keith A ; Reynolds, David S</creatorcontrib><description>The majority of inhibitory neurotransmission in the brain is mediated by the gamma-aminobutyric acid (GABA) type A (GABA(A)) receptor. The anticonvulsant loreclezole largely acts by potentiating GABA(A) receptors containing beta2 and beta3 subunits. We used a genetically modified mouse containing a loreclezole-insensitive beta2 subunit (beta2N265S) to determine the role of this subunit in mediating the sedative and anticonvulsive effects of loreclezole. Sedation was assessed by measuring spontaneous locomotor activity and beam walking performance, and anticonvulsant efficacy was determined by pentylenetetrazole (PTZ) and amygdala kindling-induced seizures. The beta2N265S mice did not exhibit loreclezole-mediated sedation as shown by normal locomotor activity and beam walking performance. However, loreclezole also failed to provide significant protection against PTZ-induced seizures in the beta2N265S mice. Reduced efficacy against amygdala-kindled seizures, both acutely and over a 13-day chronic dosing study, was also observed in beta2N265S mice. These results suggest that the majority of the sedative effects and a significant proportion of the anticonvulsant efficacy of loreclezole are mediated via beta2-containing GABA(A) receptors.</description><identifier>ISSN: 0953-816X</identifier><identifier>PMID: 16882014</identifier><language>eng</language><publisher>France</publisher><subject>Animals ; Anticonvulsants - pharmacology ; Female ; Hypnotics and Sedatives - pharmacology ; Male ; Mice ; Mice, Mutant Strains ; Point Mutation ; Receptors, GABA - genetics ; Receptors, GABA - physiology ; Triazoles - pharmacology</subject><ispartof>The European journal of neuroscience, 2006-07, Vol.24 (1), p.167-174</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16882014$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Groves, James O</creatorcontrib><creatorcontrib>Guscott, Martin R</creatorcontrib><creatorcontrib>Hallett, David J</creatorcontrib><creatorcontrib>Rosahl, Thomas W</creatorcontrib><creatorcontrib>Pike, Andrew</creatorcontrib><creatorcontrib>Davies, Amy</creatorcontrib><creatorcontrib>Wafford, Keith A</creatorcontrib><creatorcontrib>Reynolds, David S</creatorcontrib><title>The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole</title><title>The European journal of neuroscience</title><addtitle>Eur J Neurosci</addtitle><description>The majority of inhibitory neurotransmission in the brain is mediated by the gamma-aminobutyric acid (GABA) type A (GABA(A)) receptor. The anticonvulsant loreclezole largely acts by potentiating GABA(A) receptors containing beta2 and beta3 subunits. We used a genetically modified mouse containing a loreclezole-insensitive beta2 subunit (beta2N265S) to determine the role of this subunit in mediating the sedative and anticonvulsive effects of loreclezole. Sedation was assessed by measuring spontaneous locomotor activity and beam walking performance, and anticonvulsant efficacy was determined by pentylenetetrazole (PTZ) and amygdala kindling-induced seizures. The beta2N265S mice did not exhibit loreclezole-mediated sedation as shown by normal locomotor activity and beam walking performance. However, loreclezole also failed to provide significant protection against PTZ-induced seizures in the beta2N265S mice. Reduced efficacy against amygdala-kindled seizures, both acutely and over a 13-day chronic dosing study, was also observed in beta2N265S mice. These results suggest that the majority of the sedative effects and a significant proportion of the anticonvulsant efficacy of loreclezole are mediated via beta2-containing GABA(A) receptors.</description><subject>Animals</subject><subject>Anticonvulsants - pharmacology</subject><subject>Female</subject><subject>Hypnotics and Sedatives - pharmacology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Mutant Strains</subject><subject>Point Mutation</subject><subject>Receptors, GABA - genetics</subject><subject>Receptors, GABA - physiology</subject><subject>Triazoles - pharmacology</subject><issn>0953-816X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNo1kD1PwzAQhjOAaCn8BeSJLZIdf8QZSwUFqRJLB7bIds5g5NohdirBr8cVZbqv931OdxfVEnec1pKIt0V1ndInxlgKxq-qBRFSNpiwZXXcfwCaogcULdquH9YasmpQmvUcXK5NDFm54MI7msDAmOOUkAvoAINT-dTOxa9CdkV5nH0qaSkHlGAo8yMgsBZMTie8j4Xh4adsu6kurfIJbs9xVe2fHveb53r3un3ZrHf1yBmrhdJmkERio5kk2HakU1oRQQm3RnYt5q2xA6eUS8powzgTWgkhDTG02Aa6qu7_sOMUv2ZIuT-4ZMB7FSDOqReyxS2luAjvzsJZl9v6cXIHNX33_4-iv5ktZL4</recordid><startdate>200607</startdate><enddate>200607</enddate><creator>Groves, James O</creator><creator>Guscott, Martin R</creator><creator>Hallett, David J</creator><creator>Rosahl, Thomas W</creator><creator>Pike, Andrew</creator><creator>Davies, Amy</creator><creator>Wafford, Keith A</creator><creator>Reynolds, David S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200607</creationdate><title>The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole</title><author>Groves, James O ; Guscott, Martin R ; Hallett, David J ; Rosahl, Thomas W ; Pike, Andrew ; Davies, Amy ; Wafford, Keith A ; Reynolds, David S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p544-6abcd8180cb4810f919aba16315fc897057cfd5335834324546ba668c1c3818d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Anticonvulsants - pharmacology</topic><topic>Female</topic><topic>Hypnotics and Sedatives - pharmacology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Mutant Strains</topic><topic>Point Mutation</topic><topic>Receptors, GABA - genetics</topic><topic>Receptors, GABA - physiology</topic><topic>Triazoles - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Groves, James O</creatorcontrib><creatorcontrib>Guscott, Martin R</creatorcontrib><creatorcontrib>Hallett, David J</creatorcontrib><creatorcontrib>Rosahl, Thomas W</creatorcontrib><creatorcontrib>Pike, Andrew</creatorcontrib><creatorcontrib>Davies, Amy</creatorcontrib><creatorcontrib>Wafford, Keith A</creatorcontrib><creatorcontrib>Reynolds, David S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The European journal of neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Groves, James O</au><au>Guscott, Martin R</au><au>Hallett, David J</au><au>Rosahl, Thomas W</au><au>Pike, Andrew</au><au>Davies, Amy</au><au>Wafford, Keith A</au><au>Reynolds, David S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole</atitle><jtitle>The European journal of neuroscience</jtitle><addtitle>Eur J Neurosci</addtitle><date>2006-07</date><risdate>2006</risdate><volume>24</volume><issue>1</issue><spage>167</spage><epage>174</epage><pages>167-174</pages><issn>0953-816X</issn><abstract>The majority of inhibitory neurotransmission in the brain is mediated by the gamma-aminobutyric acid (GABA) type A (GABA(A)) receptor. The anticonvulsant loreclezole largely acts by potentiating GABA(A) receptors containing beta2 and beta3 subunits. We used a genetically modified mouse containing a loreclezole-insensitive beta2 subunit (beta2N265S) to determine the role of this subunit in mediating the sedative and anticonvulsive effects of loreclezole. Sedation was assessed by measuring spontaneous locomotor activity and beam walking performance, and anticonvulsant efficacy was determined by pentylenetetrazole (PTZ) and amygdala kindling-induced seizures. The beta2N265S mice did not exhibit loreclezole-mediated sedation as shown by normal locomotor activity and beam walking performance. However, loreclezole also failed to provide significant protection against PTZ-induced seizures in the beta2N265S mice. Reduced efficacy against amygdala-kindled seizures, both acutely and over a 13-day chronic dosing study, was also observed in beta2N265S mice. These results suggest that the majority of the sedative effects and a significant proportion of the anticonvulsant efficacy of loreclezole are mediated via beta2-containing GABA(A) receptors.</abstract><cop>France</cop><pmid>16882014</pmid><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0953-816X |
ispartof | The European journal of neuroscience, 2006-07, Vol.24 (1), p.167-174 |
issn | 0953-816X |
language | eng |
recordid | cdi_proquest_miscellaneous_68707330 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Animals Anticonvulsants - pharmacology Female Hypnotics and Sedatives - pharmacology Male Mice Mice, Mutant Strains Point Mutation Receptors, GABA - genetics Receptors, GABA - physiology Triazoles - pharmacology |
title | The role of GABAbeta2 subunit-containing receptors in mediating the anticonvulsant and sedative effects of loreclezole |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A47%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20GABAbeta2%20subunit-containing%20receptors%20in%20mediating%20the%20anticonvulsant%20and%20sedative%20effects%20of%20loreclezole&rft.jtitle=The%20European%20journal%20of%20neuroscience&rft.au=Groves,%20James%20O&rft.date=2006-07&rft.volume=24&rft.issue=1&rft.spage=167&rft.epage=174&rft.pages=167-174&rft.issn=0953-816X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E68707330%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p544-6abcd8180cb4810f919aba16315fc897057cfd5335834324546ba668c1c3818d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68707330&rft_id=info:pmid/16882014&rfr_iscdi=true |